Key Takeaways
- Tough quarter, no quick fix: Domestic crop care revenue fell 5% YoY as a dry spell hit herbicide demand, while international markets stayed under severe pricing and destocking pressure; management expects the pain to persist well into Q3 and perhaps the full financial year.
- Margins held through mix, not volume: Gross margin improved despite the top-line pressure, driven by a favorable shift toward higher-margin insecticides and cost optimization, showing the portfolio lever is working even when demand is not.
- The seeds business is turning a corner: Lower sales returns and strong cotton hybrid performance drove a visible improvement in seeds profitability, though the business remains heavily skewed toward Kharif for at least another year.
- New capacity is coming online now: The Dahej multipurpose plant is commercializing its first contract manufacturing product this quarter, and the new in-house technical Difenoconazole has been launched, marking the start of a multi-year ramp-up.
- What to watch next quarter: Whether Rabi sowing is materially hit by low reservoir levels, any sign of channel inventory normalization in exports, and the pace of ramp-up at the new Dahej plant.
Demand Environment
- Domestic market hit by weather, not demand destruction: A long dry spell and erratic spatial distribution of rains decelerated key emergent herbicide sales and impacted post-emergent herbicide demand; insecticides grew volumetrically while fungicides de-grew, and herbicides stayed flat.
- Industry-wide pricing pressure: Distressed selling by some players and Chinese pricing pressure weighed on the domestic market, though management noted some stability in prices toward the end of the quarter for a few molecules.
- International markets remain the bigger drag: Volume growth stayed muted against high channel inventory, with pricing pressure continuing for Acephate, Hexaconazole and Metribuzin; the company adopted shorter buying and pricing cycles to manage risk and cleared inventory even at lower margins to avoid significant markdowns.
- Global agrochemical market reset is slow: The industry swelled from $60–$65 billion to $80 billion in two years, and working out that flab will take time; leading global players now expect a low double-digit market decline, worse than earlier low single-digit guidance.
- Rabi season at risk: Peninsular India reservoir levels are significantly lower than the long-period average, and management is factoring the likely adverse impact on Rabi sowing into its plans.
Nagarajan: "the global agrochemical business went up to $80 billion, from about $60 billion, $65 billion in two years. So there is a kind of a process of working out this flab, which is going to take some time. It's hard to predict when the green shoots will emanate."
Margin & Cost Management
- Gross margin improved on mix, not pricing power: Better product mix, with volumetric growth in higher-margin insecticides and flat herbicides, lifted gross margin; cost optimization in crop care and seeds added further support.
- Fixed costs held tight: Management stayed prudent on fixed costs while scaling up new launches; some products received trade schemes to drive volumes, but overall spending discipline was maintained.
- Other expenses fell meaningfully: Freight and distribution costs compressed on both volumes and rates; optimization in bad debt, traveling and conveyance, plus better spending visibility and controls, contributed to the decline.
- High-cost inventory largely cleared: Most high-cost inventory has been navigated without significant markdown impact; a small residual quantum may remain, but management is confident of liquidating it through export or domestic branded formulations.
- Portfolio mix is the margin lever going forward: Management will actively manage the mix between domestic, international, CSM, crop nutrition and seeds, and within domestic between insecticides, fungicides and herbicides, to protect margins on an annualized basis.
Seeds Business Turnaround
- Kharif performance was satisfactory: The Diggaz cotton hybrid sold well in northern markets and Aatish performed well in South and Central India; the company made steady progress across Paddy, Maize and Millets, increasing market share in North India.
- Lower sales returns drove the Q2 profit improvement: Special ground-level efforts in Q1 demonstrated product differentiation for key hybrids, leading to good liquidation and lower sales returns, which flowed through in Q2 when actual returns were accounted for.
- Strategic reset is underway: Based on a strategic review, the company prioritized resources and expenditures on key geographies and crop segments to improve unit economics; management is hopeful the trend improves over the coming years.
- Kharif skew persists: The seeds business will remain skewed toward Kharif for this year and perhaps next, until the Rabi portfolio is sorted out.
Sanjiv Lal: "The seed business, as you're aware, has gone to a rough phase in the last couple of years, but we are hopeful of this trend improving over the coming years."
New Capacity & Product Pipeline
- Dahej multipurpose plant is going live: The first contract manufacturing active ingredient will be produced in Q3 for a specific customer, not for the East Asian market; one more CSM product is ready to be commercialized during the current quarter from the same plant.
- Difenoconazole commercialized: The new in-house technical, the first product introduced through the MPP route, has been commercialized; two formulated products based on it were launched domestically this quarter, and the company aims to supply the technical internationally and formulations where registrations permit.
- Pendimethalin capacity expansion under evaluation: Technical equivalence received for the European market last year opened EU sales, pendi-based formulations and mixtures are gaining traction overseas, and strong demand for the CS formulation supports confidence to expand capacity.
- New product pipeline progressing: The pipeline is advancing through lab-scale, KG-scale and pilot-scale stages; management is confident of progressively launching new products, including one new catalogue product every year that will scale over time.
- Difenoconazole scale-up will take time: Management expects to scale up maybe in a couple of years, with a better roadmap once further advanced in the registration process; initial sales will target Southeast Asian and unregulated markets, then expand.
Balance Sheet & Cash Flow
- Zero-debt status achieved: Rallis became a zero-debt company except for a small sales tax deferral loan.
- Cash flow improved: Specific focus on inventory reduction and collections in both domestic and international markets drove the improvement.
- Quality of sales and cash flow remain key priorities: Management will focus on improving collections and controlling inventories during H2.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pain to persist | Situation to continue well into Q3 and perhaps the rest of FY24; volume-led growth with pricing likely negative | Q3 FY24 / full FY24 |
| Next quarter difficulty | "At least the next quarter is not going to be easy, that's for sure" | Q3 FY24 |
| Channel inventory normalization | At least after this quarter; whether Q4 or later, will have to wait | Q4 FY24 or beyond |
| First CSM product from Dahej | Producing first active ingredient for a specific customer | Q3 FY24 (current quarter) |
| One more CSM product commercialization | Ready to be commercialized from Dahej multipurpose plant | Q3 FY24 (current quarter) |
| Seeds business skewness | Skewness toward Kharif will continue | This year and perhaps next year |
| Difenoconazole scale-up | Expects to scale up maybe in a couple of years | ~2 years |
| One new catalogue product per year | Will introduce one every year; over time these will scale | Annual, ongoing |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue | ₹832 cr, lower by 12% YoY from ₹951 cr |
| EBITDA | ₹133 cr, higher by 13% YoY from ₹118 cr |
| EBITDA margin | 16%, improved from 12% in Q2 FY23 |
| PAT | ₹82 cr, higher from ₹72 cr in Q2 FY23 |
| PAT margin | 10%, improved YoY |
| Domestic Crop Care revenue growth | -5% YoY, entirely from price decline; volumes flat to marginally positive |
| International business revenue decline | ~10–15% from price drop, balance from volume decline |
| Seeds business revenue growth | 237% YoY, driven by small base and lower sales returns |
| Seeds business H1 growth | 21% positive on a first-half basis |
| Domestic:International revenue mix | 4:1 for the quarter |
| Gross margin drivers | Improved through superior product mix and cost efficiencies in Crop Care and Seeds |
| Working capital loans repaid in Q2 | ₹75 cr repaid; company became zero-debt except for sales tax deferral loan of ₹2.66 cr |
| Capex guidance for FY24 | ~₹150 cr envisaged for the full year |
| Domestic Crop Care distribution network | ~4,900 distributors and retail footprint of ~61,800 as of September-end |
| Seeds distribution network | 2,750 distributors and retail footprint of ~47,000 as of quarter-end |
| New products launched in H1 FY24 | 11 products introduced across segments and geographies |
| Diggaz cotton hybrid sales | A little more than 4 lakh packets sold |
| Distribution overlap (Seeds and Crop Protection) | 25–30% common distributors between the two businesses |